Albeit with a different genome-editing technology, good responses were seen with the anti-CD19 allo CAR-T-cell PBCAR0191 (azercabtagene zapreleucel) following an enhanced lymphodepletion chemotherapy regimen in B-ALL and B-NHL. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.